Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression

NCT05777278 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Savolitinib
DRUG: Docetaxel

Sponsor

The First Affiliated Hospital of Guangzhou Medical University